The US Food and Drug Administration (FDA) has approved BMEYE's ccNexfin, a totally noninvasive cardiovascular monitor with blood pressure, cardiac output, and Masimo rainbow SET Pulse CO-Oximetry measurements.
The combination of two innovative noninvasive technologies – BMEYE for cardiovascular monitoring and Masimo rainbow SET for noninvasive and continuous hemoglobin and oxygen saturation monitoring – provides real-time, beat-to-beat measurements of cardiac, circulatory, and pulmonary parameters, which may enable clinicians to detect impending cardiovascular crisis before organ injury ensues in critical care.
The ccNexfin utilises a BMEYE finger cuff to capture and continuously measure beat-to-beat blood pressure (sys/dia), mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), and derivative of pressure (dP/dt), and a Masimo finger sensor to noninvasively and continuously measure hemoglobin (SpHb(R)), oxygen saturation (SpO2), oxygen content (SpOC(TM)), and perfusion index (PI).
This detailed data allows clinicians to predict and proactively address the early signs of hemodynamic instability during critical situations rather than reacting to late indicators and their effects, BMEYE said.
BMEYE, a Dutch company based in Amsterdam, The Netherlands, develops medical devices with broad application in clinical settings that require cardiovascular monitoring. Specifically, BMEYE produces patient monitors that noninvasively measure continuous blood pressure and cardiac output.